A practical reference on Research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-10 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Kipa-Williams enjoyed working with Samson, as they got along well and he believed that showed on-screen as Ari and Mia reconcile. He also praised Barrett and explained how they got the chance to explore their characters' histories together, saying "you'll get to see a softer side of Ari in the way that Sam plays her character. And I think people will be surprised at the father figure that he has forgotten he is, or was." The first test of Ari and Mia's new relationship is his involvement with a criminal gang headed up by Paul (Jack Finsterer), which leads to the kidnapping of Chloe, Nikau, Bella, and Ryder Jackson (Lukas Radovich). Mia decides to leave the Bay with Chloe and tells Ari that she regrets letting him back into her life. Kipa-Williams commented that "Ari is heartbroken – he's faced with losing the love of his life." He sympathised with Mia, who is angry about her daughter being kidnapped. He also pointed out that Mia thought Ari had changed, so it "pains" her to think that he is still the same man who could end up in prison again. As Ari is walking along the road, he calls Chloe before she leaves town, and is struck by a car driven by Paul who then speeds off. Kipa-Williams said Ari is "blindsided" by the attack and described it as "a ruthless hit-and-run". Ari suffers multiple injuries and has to be placed in a medically induced coma due to a bleed on the brain. Following Ari's recovery, writers scripted a pregnancy for Mia after the couple agree to try for a baby.
=== Systematic reviews identifying safety signals === A 2013 comprehensive systematic review by Dr. Salvatore Gentile concluded that second‑generation long‑acting injectable antipsychotics (SGA‑LAIs) "seem to also show unforeseen and worrisome safety signals," and noted that "worsening of psychotic symptoms and depression could also be associated with both risperidone‑LAI and paliperidone palmitate." The leading cause of death among patients enrolled in risperidone‑LAI studies was suicide. A 2017 systematic update by the same author concluded that SGA‑LAIs "do not offer advantages in safety compared with first‑generation antipsychotic LAIs or oral antipsychotics," and highlighted weight gain, hyperprolactinemia, and the finding that the three‑monthly paliperidone palmitate formulation still lacked exhaustive safety data.
The northernmost, Atlasov Island (Araido in Japanese), is an almost-perfect volcanic cone rising sheer out of the sea; it has been depicted by Japanese artists in haiku, wood-block prints, and other forms, in much the same way as the better-known Mount Fuji. Its summit is the highest point in Sakhalin Oblast.
Sources: en.wikipedia.org
=== 2013 class action lawsuit === In 2013, a proposed class action lawsuit, Jennifer L Saavedra v. Eli Lilly and Company, was brought against Eli Lilly claiming that the Cymbalta label omitted important information about "brain zaps" and other symptoms upon cessation. Eli Lilly moved for dismissal per the "learned intermediary doctrine" as the doctors prescribing the drug were warned of the potential problems and are an intermediary medical judgment between Lilly and patients; in December 2013, Lilly's motion to dismiss was denied. In December 2014, class certification was denied. A second attempt at certification in 2015 also failed.
== Powers == Article 11.(a) lists 17 political powers held by the Sovereignty Council, including the appointment of the Prime Minister, confirmation of leaders of certain state bodies, the right to declare war or a state of emergency, and signing and ratifying national and international agreements.
Several small-scale studies involving 15 or fewer test subjects conducted in the 1950s and 1960s reported that adrenochrome triggered psychotic reactions such as thought disorder and derealization. In 1954, researchers Abram Hoffer and Humphry Osmond claimed that adrenochrome is a neurotoxic, psychotomimetic substance and may play a role in schizophrenia and other mental illnesses. In what Hoffer called the "adrenochrome hypothesis", he and Osmond in 1967 speculated that megadoses of vitamin C and niacin could cure schizophrenia by reducing brain adrenochrome. The treatment of schizophrenia with such potent anti-oxidants is controversial. In 1973, the American Psychiatric Association reported methodological flaws in Hoffer's work on niacin as a schizophrenia treatment and referred to follow-up studies that did not confirm any benefits of the treatment. Multiple additional studies in the United States, Canada, and Australia similarly failed to find benefits of megavitamin therapy to treat schizophrenia. The adrenochrome theory of schizophrenia waned, despite some evidence that it may be psychotomimetic, as adrenochrome was not detectable in people with schizophrenia. In the early 2000s, interest was renewed by the discovery that adrenochrome may be produced normally as an intermediate in the formation of neuromelanin. This finding may be significant because adrenochrome is detoxified at least partially by glutathione-S-transferase. Some studies have found genetic defects in the gene for this enzyme. Adrenochrome is also believed to have cardiotoxic properties.
=== Mechanism of action === Meropenem is bactericidal except against Listeria monocytogenes, where it is bacteriostatic. It inhibits bacterial cell wall synthesis like other β-lactam antibiotics. In contrast to other β-lactams, it is highly resistant to degradation by β-lactamases or cephalosporinases. In general, resistance arises due to mutations in penicillin-binding proteins, production of metallo-β-lactamases, or resistance to diffusion across the bacterial outer membrane. Unlike imipenem, it is stable to dehydropeptidase-1, so can be given without cilastatin. In 2016, a synthetic peptide-conjugated PMO (PPMO) was found to inhibit the expression of New Delhi metallo-beta-lactamase 1, an enzyme that many drug-resistant bacteria use to destroy carbapenems.
Sources: en.wikipedia.org
The healing of trauma to the outer anulus fibrosus may also result in the innervation of the scar tissue and pain impulses from the disc, as these nerves become inflamed by nucleus pulposus material. Degenerative disc disease can lead to a chronic debilitating condition and can reduce a person's quality of life. When pain from degenerative disc disease is severe, traditional nonoperative treatment may be ineffective.
=== Extraction methods === Ossein can be isolated by treating bones with hydrochloric acid, which dissolves the inorganic matrix (calcium phosphate and calcium carbonate). The process was discovered no later than 15th century but only really spread in the 18th century, after Glauber's publications. The resulting liquor carrying calcium chloride and phosphoric acid may then be treated with calcium hydroxide to recover dicalcium phosphate for fertilizers or animal feed supplement. However, the most popular technique of treating the bone meal is steaming or boiling. This process requires no acid but much more energy and may also produce tricalcium phosphate. As an alternative, the deproteinized bone residue left after the removal of ossein can be used to produce bone ash for the manufacture of bone china.
== Micellization and phase transitions == An important characteristic of poloxamer solutions is their temperature dependent self-assembling and thermo-gelling behavior. Concentrated aqueous solutions of poloxamers are liquid at low temperature and form a gel at higher temperature in a reversible process. The transitions that occur in these systems depend on the polymer composition (molecular weight and hydrophilic/hydrophobic molar ratio). At low temperatures and concentrations (below the critical micelle temperature and critical micelle concentration) individual block copolymers (unimers) are present in solution. Above these values, aggregation of individual unimers occurs in a process called micellization. This aggregation is driven by the dehydration of the hydrophobic polyoxypropylene block that becomes progressively less soluble as the polymer concentration or temperature increases. The aggregation of several unimers occurs to minimize the interactions of the PPO blocks with the solvent. Thus, the core of the aggregates is made from the insoluble blocks (polyoxypropylene) while the soluble portion (polyoxyethylene) forms the shell of the micelles.
== Structure == BOLD-100 has an octahedral structure with two trans indazoles and four chloride ligands in the equatorial plane. The primary cation for BOLD-100 is sodium. BOLD-100's impurity profile contains trace quantities of cesium
== Death row conditions == A 1978 newspaper article described the death row section of the original Changi Prison as consisting of 24 cells arranged in a horse shoe shaped block around an open air grassy exercise yard. The exercise area itself was enclosed in steel bars and had a wire mesh roof to prevent escape by helicopter. Amnesty International reports that death row inmates are housed in cells of roughly three square metres (32 square feet). Walls make up three sides, while the fourth is made up of vertical bars. They are equipped with a toilet, a sleeping mat, and a bucket for washing. Exercise is permitted twice a day for half an hour at a time. Four days before the execution, the condemned is allowed to watch television or listen to the radio. Special meals of their choice are also cooked, if within the prison budget. In 1994, inmates had a budget of S$22 for their last meal. One documented last meal of an inmate was the last meal order of Tangaraju Suppiah, who asked for chicken rice, ice cream soda, nasi biryani and Milo-flavoured sweets before his hanging, while another was John Martin Scripps, who ordered a pizza and a cup of hot chocolate before his execution. Visiting rights are increased from one 20-minute visit per week to a maximum of four hours each day, though no physical contact is allowed with any visitors. In addition, two days before an execution, an inmate is allowed to have a photo shoot and be given their own clothes to pose during a photoshoot; the photo will be given to their families as remembrance.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.